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Background: The benefit of induction chemotherapy in locally advanced oral squamous cell carcinoma (OSCC)
remains to be clearly defined. Induction chemotherapy is likely to be effective for biologically distinct subgroups of
patients and biomarker development might lead to identification of the patients whose tumors are to respond to a
particular treatment. Annexin A1 may serve as a biomarker for responsiveness to induction chemotherapy. The aim
of this study was to investigate Annexin A1 expression in pre-treatment biopsies from a cohort of OSCC patients
treated with surgery and post-operative radiotherapy or docetaxel, cisplatin and 5-fluorouracil (TPF) induction
chemotherapy followed by surgery and post-operative radiotherapy. Furthermore we sought to assess the utility of
Annexin A1 as a prognostic or predictive biomarker.
Methods: Immunohistochemical staining for Annexin A1 was performed in pre-treatment biopsies from 232 of
256 clinical stage III/IVA OSCC patients. Annexin A1 index was estimated as the proportion of tumor cells (low and
high, <50% and ≥50% of stained cells, respectively) to Annexin A1 cellular membrane and cytoplasm staining.
Results: There was a significant correlation between Annexin A1 expression and pathologic differentiation grade
(P=0.015) in OSCC patients. The proportion of patients with low Annexin A1 expression was significantly higher
amongst those with moderate/poorly differentiated tumor (78/167) compared to those with well differentiated tumor
(18/65). Multivariate Cox model analysis showed clinical stage (P=0.001) and Annexin A1 expression (P=0.038) as
independent prognostic risk factors. Furthermore, a low Annexin A1 expression level was predictive of longer disease-
free survival (P=0.036, HR=0.620) and locoregional recurrence-free survival (P=0.031, HR=0.607) compared to high
Annexin A1 expression. Patients with moderate/poorly differentiated tumor and low Annexin A1 expression benefited
from TPF induction chemotherapy as measured by distant metastasis-free survival (P=0.048, HR=0.373) as well as
overall survival (P=0.078, HR=0.410).
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Conclusions: Annexin A1 can be used as a prognostic biomarker for OSCC. Patients with moderate/poorly
differentiated OSCC and low Annexin A1 expression can benefit from the addition of TPF induction chemotherapy to
surgery and post-operative radiotherapy. Annexin A1 expression can potentially be used as a predictive biomarker to
select OSCC patients with moderate/poorly differentiated tumor who may benefit from TPF induction chemotherapy.
Keywords: Annexin A1, Oral squamous cell carcinoma, Induction chemotherapyBackground
Oral squamous cell carcinoma (OSCC) is the most com-
mon type of head and neck cancer. Patients with OSCC
have poor clinical outcomes including treatment related
organ dysfunction. The 5-year survival rate of OSCC pa-
tients is 50-60% [1,2]. To improve the clinical manage-
ment of OSCC patients, it is important to develop
different treatment strategies and ways to determine
which subgroup of patients respond mostly to various
strategies. Currently, the most common treatment for
patients with locally advanced and resectable OSCC is
radical surgery followed by post-operative radiotherapy
or chemoradiotherapy depending on the presence of
high-risk features in the surgical specimen. Clinically,
only clinical staging and pathologic differentiation grade
are used to predict prognosis of OSCC patients [3-5].
Therefore, it is critical to understand the biological basis
of OSCC and develop novel biomarkers that can help
predict the prognosis and likelihood that a patient bene-
fits from a particular treatment strategy.
Induction chemotherapy is regarded as an effective
way to reduce locally advanced or aggressive cancers, to
improve the chance of eradication of locoregional lesions
by radical surgery and/or radiotherapy/chemoradiotherapy,
and to preserve end-organ functionality to ultimately
maintain a high quality of life. Recently, two randomized
phase 3 trials (TAX323 and TAX324) demonstrated that
induction chemotherapy protocol of docetaxel, cisplatin
and 5-fluorouracil (TPF) combination followed by radio-
therapy or chemoradiotherapy can improve overall survival
(OS) compared to cisplatin and 5-fluorouracil (PF) in head
and neck squamous cell carcinoma (HNSCC) patients
[6-8]. However, it is still unknown whether TPF induction
chemotherapy improves outcomes when given prior to sur-
gery in patients with locally advanced HNSCC, especially
OSCC. To address the role of induction TPF in OSCC
treated with surgery, we conducted a randomized phase 3
trial of induction TPF followed by surgical resection versus
surgical resection in patients with locally advanced OSCC
[9]. We failed to demonstrate a survival advantage for in-
duction chemotherapy in the overall study population. It is
possible, however, that induction chemotherapy with TPF
might improve outcomes in a molecularly defined sub-
group of patients. Correlative studies from the aforemen-
tioned randomized trials could assist in identifyingcandidate biomarkers predictive of benefit from induction
treatment.
Annexin A1 is an intracellular protein that can bind
calcium and phospholipids. It has been suggested to
have an important role in the inflammation response,
cell proliferation, cell signaling, phagocytosis, and car-
cinogenesis [10]. Although there is still controversy re-
garding Annexin A1 expression in different types of
cancers, including breast, pancreatic, hepatic, prostate,
urothelial, cervical, and head and neck cancer [11-27],
low Annexin A1 expression correlates with poor patho-
logic differentiation grade [11-15]. In fact, absence of
Annexin A1 expression has been reported to correlate
with a poor pathologic response to induction chemo-
therapy in breast cancer [28]. However, the clinical use-
fulness of Annexin A1 expression in OSCC is not well
understood. Specifically, it is unknown if Annexin A1
expression in the pre-treatment biopsy from OSCC pa-
tients can be used as a prognostic biomarker or an indi-
cation for induction chemotherapy.
The aim of the present study was to evaluate Annexin
A1 expression in the pre-treatment biopsy specimens
from patients with resectable locally advanced OSCC.
These patients had been enrolled in a randomized phase
3 trial of TPF induction chemotherapy followed by sur-
gery and post-operative radiotherapy compared to sur-
gery and post-operative radiotherapy. Furthermore we
aimed to examine the possible prognostic and predictive
role of Annexin A1expression in this patient population.
We hypothesize that low Annexin A1 expression plays a
role in survival of patients with OSCC, and is also predict-
ive of patient benefit from TPF induction chemotherapy.
Methods
Patients
256 patients with primary and locally advanced OSCC
were enrolled in a prospective, randomized, phase 3 trial
at Ninth People’s Hospital, Shanghai Jiao Tong Univer-
sity School of Medicine [9], which was in compliance
with the Helsinki Declaration. The aim of this study was to
test the hypothesis that TPF induction chemotherapy ad-
ministered prior to surgery and post-operative radiotherapy
improves survival in patients with resectable locally ad-
vanced OSCC (trial registration ID: NCT01542931). After
eligibility was confirmed and written informed consent
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(surgery followed by post-operative radiotherapy) or ex-
perimental group (TPF induction chemotherapy followed
by surgery and post-operative radiotherapy).
The TPF induction chemotherapy consisted of docetaxel
75 mg/m2 intravenously and cisplatin 75 mg/m2 intraven-
ously on day 1, followed by 5-fluorouracil 750 mg/m2/day
as a 120-hour continuous intravenous infusion on days 1
through 5. Induction chemotherapy was given every 3
weeks for 2 cycles. Surgery was performed at least 2 weeks
after completion of induction chemotherapy, consisting of
radical resection of the primary lesion and full neck
dissection with appropriate reconstruction (pedicle or
free flap); frozen sections during surgery was performed
to confirm adequate margins. Post-operative radiother-
apy was initiated 4–6 weeks after surgery, at a dose of
1.8-2 Gy/day, 5 days/week for 6 weeks, totally 54-60 Gy;
in patients with high risk features, such as positive surgical
margins, extracapsular nodal spread, or vascular embol-
ism, a total radiation dose of 66 Gy was recommended.
Clinical tumor response to induction chemotherapy
was determined by clinical evaluation and imaging stud-
ies (performed at baseline and 2 weeks after cycle 2 of
induction chemotherapy). Responses were characterized
according to the RECIST version 1.0 [29]. Pathologic re-
sponse to TPF induction chemotherapy was assessed by
examination of the resected specimen. A favorable re-
sponse was defined as absence of tumor cells or pres-
ence of scattered foci of a few tumor cells (minimal
residual disease with <10% viable tumor cells), as previ-
ously described by Licitra et al. [30]; an unfavorable patho-
logic response was defined as the presence of ≥10% viable
tumor cells in the resected specimen.
After treatment, patients were monitored every three
months in the first two years, every six months in the
subsequent 3–5 years, and once a year thereafter until
death or data censoring.Detection of Annexin A1 expression using
immunohistochemistry
Pre-treatment formalin fixed and paraffin embedded bi-
opsy specimens were used for detection of Annexin A1
expression; however, in the control group, if pre-
treatment biopsy was unavailable, resected surgical spec-
imens were used. Sections of 4 μm thick were studied
using hematoxylin and eosin (HE) staining and immuno-
histochemical staining for Annexin A1. The HE sections
were reviewed according to the WHO histological cri-
teria [31]. Immunohistochemical staining was accom-
plished using well established methods as previously
described [32,33]. In brief, after deparaffinization, en-
dogenous peroxidase block and heat-induced epitope re-
trieval, primary rabbit polyclonal antibody to AnnexinA1 (product code of BA0640, Boster Biotech Co., Wuhan,
China) at 1:150 dilution was added overnight at 4°C, then
visualized using 3,3’-diaminobenzidine (DAB) detection
kit (Dako Cytomation, Denmark). The 1:150 dilution was
the best dilution compared to 1:50, 1:100, and 1:200.
Negative control was prepared using PBS instead of anti-
body. Microscopic examination was performed by two pa-
thologists and all specimens were blinded. Positive
staining for Annexin A1 expression was observed in the
cellular membrane and cytoplasm. The Annexin A1 ex-
pression index was determined based on the proportion of
stained cells on a scale of negative to strong as follows:
negative, absence of stained cells; weak positive, <50% of
stained cells; and strong positive, ≥50% of stained cells.
Low Annexin A1 expression was defined as negative and
weak positive Annexin A1 expression, high Annexin A1
expression was defined as strong positive Annexin A1
expression. This was based on previous studies demon-
strating that the chosen cut-off of 50% was reasonable for
prognostic analysis [24].Statistical analysis
The primary endpoint of this trial was survival rate. Sec-
ond endpoints of this trial were local control and safety.
Overall survival (OS) was calculated from the date of
randomization to the date of death; disease-free survival
(DFS)/locoregional recurrence-free survival (LRFS)/distant
metastasis-free survival (DMFS) were calculated, respect-
ively, from the date of randomization to recurrence/
locoregional recurrence/distant metastasis or death from
any cause.
For descriptive analysis, categorical data were expressed
as number and percentage. Chi-square test was applied
to compare the difference between the baseline factors
and Annexin A1 expression. The survival analysis was
conducted using the Kaplan-Meier method and log-
rank test. Hazard ratios (HR) were calculated using the
Cox proportional hazards model. Intention-to-treat
principle was applied for efficacy analysis.
All hypothesis-generating tests were two-sided at a sig-
nificance level of 0.05. Data were analyzed with the stat-
istical software SPSS13.0 for Windows (SPSS Inc., USA).Results
Annexin A1 expression in OSCC patients
From 03/2008 to 12/2010, 256 eligible patients were en-
rolled in this trial (128 patients in each group). 232
(91%, 127 patients in the control group, 105 patients in
the experimental group) patients were assessed for pre-
treatment tumor Annexin A1 expression levels. Table 1
summarizes their baseline clinical characteristics, with
no significant imbalance between the two groups. 96
specimens (56 in the control group and 40 in the
Table 1 Baseline characteristics and Annexin A1
expression





n (%) n (%) n (%)
Gender
Male 179 (69.9) 72 (77.2) 88 (61.0) 0.095
Female 77 (30.1) 24 (22.8) 48 (39.0)
Age (years)
<60 168 (65.6) 67 (71.1) 90 (64.4) 0.562
≥60 88 (34.4) 29 (29.9) 46 (35.6)
Site
Tongue 113 (44.1) 42 (42.1) 56 (42.4) 0.281
Buccal 45 (17.6) 15 (17.5) 28 (20.3)
Gingiva 40 (15.6) 11 (12.3) 27 (21.1)
Floor of mouth 30 (11.7) 16 (16.7) 13 (8.5)
Palate 18 (7.0) 7 (6.1) 7 (5.9)
Retromolar trigone 10 (3.9) 5 (6.1) 5 (2.5)
Clinical T descriptor
T1/T2 66 (25.8) 23 (24.6) 38 (28.0) 0.497
T3/T4 190 (74.2) 73 (75.4) 98 (72.0)
Clinical N descriptor
N0 110 (43.0) 40 (39.5) 59 (45.8) 0.480
N1 94 (36.7) 33 (39.5) 53 (34.7)
N2 52 (20.3) 23 (21.0) 24 (19.5)
Clinical stage
III 177 (69.1) 60 (65.8) 100 (72.0) 0.074
IVA 79 (30.9) 36 (34.2) 36 (28.0)
Pathologic differentiation
Well 80 (31.2) 18 (22.8) 47 (33.1) 0.015
Moderately 165 (64.5) 71 (71.1) 85 (63.6)
Poorly 11 (4.3) 7 (6.1) 4 (3.4)
Smoking status**
Current/former 126 (49.2) 52 (56.1) 58 (39.0) 0.084
Never 130 (50.8) 44 (43.9) 78 (61.0)
Alcohol use***
Positive 98 (40.6) 44 (48.2) 44 (28.0) 0.037
Negative 158 (59.4) 52 (51.8) 92 (72.0)
*P value from the chi-square test was reported to compare the difference
between low and high Annexin A1 expression based on the different baseline
factors.
**Former/current smokers defined as at least a one pack-year history of
smoking.
***Positive alcohol use was defined as current alcohol use of more than one
drink per day for 1 year (12 ounces of beer with 5% alcohol, or 5 ounces of
wine with 12%-15% alcohol, or one ounce of liquor with 45%-60% alcohol). All
other patients were classified as negative alcohol use.
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pression, and 136 specimens (71 in the control group
and 65 in the experimental group) exhibited high
Annexin A1 expression. There was an equal distribu-
tion of Annexin A1 expression between the two groups
(Chi-square test=0.853, P=0.356). No significant differ-
ence of proportion of Annexin A1 expression was
found according to baseline characteristics with excep-
tion of pathologic differentiation grade and alcohol use
(Table 1). The proportion of patients with low Annexin
A1 expression was higher amongst patients with mod-
erate/poorly differentiated tumor (Figure 1) (78/167)
and positive alcohol use (44/88) compared to those
with well differentiated tumor (Figure 1) (18/65) and
negative alcohol use (52/144), respectively There was
no significant difference between pathologic differenti-
ation grade and alcohol use (P=0.499).
Annexin A1 expression and response to induction
chemotherapy
In the experimental group, responses by RECIST in 105
patients with assessment of Annexin A1 that initiated in-
duction chemotherapy were: 78.1% clinical response (4 pa-
tients with complete response and 78 patients with partial
response) and 18.1% clinical non-response (18 patients
with stable disease and 1 patient with progressive disease),
4 patients were unevaluable for response. Favorable and
unfavorable pathologic responses were observed in
26.7% (27/101) and 73.3% (74/101) of patients, respect-
ively. Pathologic response could not be evaluated in 4
patients. Annexin A1 expression did not correlate with
clinical response to TPF induction chemotherapy (Chi-
square test=1.073, P=0.300), or the pathologic response
to induction chemotherapy (Chi-square test=1.820,
P=0.177) (Table 2), even when stratified according to
alcohol use (Cochran’s Mantel-Haenszel test=0.313,
P=0.576 for clinical response; Cochran’s Mantel-Haenszel
test=0.488, P=0.485 for pathologic response).
Annexin A1 expression and patients’ outcomes
No patients were lost to follow-up; the median follow-
up time was 30 months among the censored patients.
There was no significant difference on OS, DFS, LRFS or
DMFS between the patients with and without TPF in-
duction chemotherapy. The estimated 2-year OS was
68.2% and 68.8% in the patients with and without TPF
induction chemotherapy, respectively. Locoregional re-
currence and distant metastasis occurred in 30.9% and
7.0%, respectively. In general, no significant difference
was seen in locoregional recurrence or distant metastasis
rates between the patients with and without TPF induc-
tion chemotherapy. However, in the experimental group,
the patients with low Annexin A1 expression had a sig-
nificantly lower local recurrence rate compared to that
Table 2 Clinical and pathologic response to TPF induction




Low High test P value
Clinical response 32 50 0.300
Clinical non-response 5 14
Favorable pathologic response 7 20
0.177
Unfavorable pathologic response 30 44
Figure 1 Immunohistochemical staining for Annexin A1 in the
pre-treatment biopsy samples from oral squamous cell
carcinoma patients. (A) Well differentiated grade, (B) Moderately
differentiated grade, (C) Poorly differentiated grade.
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that the patients with low Annexin A1 expression had a
better survival, especially the DFS (P=0.036, HR=0.620)
and LRFS (P=0.031, HR=0.607) (Figure 2). Univariate
Cox model was used to analyze the impact of baseline
characteristics on the time-to-event endpoints; AnnexinA1 expression (low vs. high), lymph node status (cN0-1
vs. cN2, or cN0 vs. cN1-2), and clinical stage (stage III
vs. stage IVA) were risk factors on OS, DFS, LRFS or
DMFS. Multivariate Cox model analysis was performed
using the risk factors of Annexin A1 expression and
clinical stage; while lymph node status (cN0-1 vs. cN2 or
cN0 vs. cN1-2) was not used because of the direct cor-
relation between clinical stage and lymph node status.
Both the clinical stage (P=0.001) and Annexin A1 ex-
pression (P=0.038) were independent risk factors. When
pathologic differentiation grade and alcohol use were
used in the multivariate Cox model analysis, only the
clinical stage (P=0.001) and Annexin A1 expression
(P=0.048) were independent risk factors.
Annexin A1 expression, pathologic differentiation grade
and patients’ outcomes
Patients with well differentiated tumor had a better out-
come than those with moderate/poorly differentiated
tumor. Pathologic differentiation grade did not have a sig-
nificant effect on outcomes of the entire cohort with re-
spect to OS (P=0.250), DFS (P=0.679), LRFS (P=0.790),
and DMFS (P=0.260). In the experimental group, patients
with well differentiated tumor had a better OS (P=0.958),
DFS (P=0.711), LRFS (P=0.711), and DMFS (P=0.972)
than those with moderate/poorly differentiated tumor.
This was similar to the control group with respect to OS
(P=0.132), DFS (P=0.415), LRFS (P=0.524), and DMFS
(P=0.162).
In patients with well differentiated tumor, there was
no significant difference in OS, DFS, LRFS or DMFS be-
tween patients treated with or without TPF induction
chemotherapy, regardless of Annexin A1 expression. In
patients with moderate/poorly differentiated tumor, low
Annexin A1 expression benefited from TPF induction
chemotherapy in OS (P=0.078, HR=0.410) and DMFS
(P=0.048, HR=0.373) (Figure 3); however, patients with
high Annexin A1 expression did not benefit from TPF
induction chemotherapy.
Discussion
In this study, we found that Annexin A1 may be used as
a prognostic biomarker in locally advanced and
Table 3 Comparison of local/regional/distant failure between low and high Annexin A1 expression in the oral
squamous cell carcinoma patients treated with or without TPF induction chemotherapy
Characteristics Annexin A1 expression Chi-square test Cochran Mantel Haenszel test
Low High P value P value
Surgery+post-operative radiotherapy
0.020
No local failure 45 52 0.348
Local failure 11 19
TPF+surgery+post-operative radiotherapy
No local failure 37 47 0.012
Local failure 3 18
Surgery+post-operative radiotherapy
0.332
No regional failure 51 60 0.268
Regional failure 5 11
TPF+surgery+post-operative radiotherapy
No regional failure 34 54 0.795
Regional failure 6 11
Surgery+post-operative radiotherapy
0.367
No distant failure 52 65 0.786
Distant failure 4 6
TPF+surgery+post-operative radiotherapy
No distant failure 40 62 0.168
Distant failure 0 3
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A1 expression indicates improved survival. Annexin A1
expression correlates with pathologic differentiation
grade of biopsy specimens from OSCC patients. A lower
Annexin A1 expression correlates with a poorer differen-
tiation grade. Furthermore, in patients with moderate/
poorly differentiated OSCC, those with low Annexin A1
expression may potentially benefit from TPF induction
chemotherapy on the aspect of OS and DMFS, especially
DMFS. Patients with low Annexin A1 expression may
benefit from TPF induction chemotherapy compared to
those with high Annexin A1 expression.
Although the precise mechanism of Annexin A1 in
cancer development and progression is still not clearly
understood, more emphasis has been placed on this pro-
tein in the field of carcinogenesis, cancer diagnosis and
cancer treatment. Annexin A1 has been previously linked
with various cancers as a tumor suppressor protein. This
includes breast cancer, head neck cancer, prostate cancer,
cervical cancer, lung cancer [11-19]. However, increased
Annexin A1 expression has also been reported in breast
cancer, bladder cancer, pancreatic cancer, liver cancer,
esophageal cancer, lung cancer [20-27]. Recently, the
prognostic value of Annexin A1 expression has been
reported in lung cancer, head neck cancer, bladder cancer
and breast cancer [18-24], most of which report AnnexinA1 overexpression indicates a poorer prognosis. In
contrast, Annexin A1 overexpression in breast cancer cor-
relates with a better survival [19]. In our study, a high
Annexin A1 expression in the biopsy specimens indicated
a poor prognosis, suggesting that Annexin A1 could be
used as a prognostic biomarker for locally advanced
OSCC. With respect to the role of Annexin A1 as a pre-
dictive biomarker for induction chemotherapy, future
studies are necessary.
The correlation between Annexin A1 expression and
pathologic differentiation grade has also been reported
in several kinds of cancers, such as thyroid cancer, cer-
vical cancer and head neck cancer [11-15,34]. In this
study, we confirmed that the correlation between
Annexin A1 expression and pathologic differentiation
grade in OSCC. The proportion of patients with low
Annexin A1 expression was higher amongst the patients
with moderate/poorly differentiated tumor than those
with well differentiated tumor. There was no significant
difference between the pathologic differentiation grade
and prognosis in both experimental and control groups.
Radical removal of primary lesions as well as full neck
dissection to eradicate as many lesions as possible may
be an important factor for this result.
Correlation between Annexin A1 expression and re-
sponse to induction chemotherapy has not been well
Figure 2 Overall survival, disease-free survival, locoregional recurrence-free survival, distant metastasis-free survival in the patients
with low and high Annexin A1 expression. A trend of low Annexin A1 expression indicating a better overall survival (A) and distant
metastasis-free survival (D) compared to high Annexin A1 expression; however, a low Annexin A1 expression significantly indicating a better
disease-free survival (B) and locoregional recurrence-free survival (C) compared to high Annexin A1 expression.
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coupled with presence of Annexin A2 expression is
reported to correlate with a poor pathological response
to induction chemotherapy in breast cancer [28]. In-
creased Annexin A1 expression is reported to correlate
with anti-cancer drug resistance in some tumor cells
in vitro [35]. In this study, we failed to find a significant
correlation between Annexin A1 expression and re-
sponse to TPF induction chemotherapy in OSCC. More-
over, Annexin A1 was found to have limited utility as a
predictive marker of clinical or pathologic response to
TPF induction chemotherapy when we looked at the en-
tire cohort of patients that received induction chemo-
therapy. However, a subgroup analysis showed that in
the patients with moderate/poorly differentiated tumor,
low Annexin A1 expression did have an OS and DMFS
benefit from TPF induction chemotherapy. This suggeststhat detection of Annexin A1 expression prior to treat-
ment can be used to guide treatment selection. One can
envision a personalized treatment scenario in which
OSCC patients with moderate/poorly differentiated
tumor and low Annexin A1 expression receive TPF in-
duction chemotherapy prior to surgery while those
with high Annexin A1 expression, receive surgery to
avoid the toxicity from chemotherapeutic agents and
the delay of definitive treatment. A limitation of our
study is a small sample size of 78 patients with low
Annexin A1 expression who were used for subgroup
analysis. As such, these results need to be considered
exploratory and hypothesis generating, and clearly
need to be confirmed in further clinical trials with lar-
ger sample sizes.
In addition to our findings related to Annexin A1
expression, other biomarkers have been evaluated as
Figure 3 In patients with moderate/poorly differentiated tumor, those with low Annexin A1 expression benefited from TPF induction
chemotherapy on overall survival (A) and distant metastasis-free survival (D), but not benefit from TPF induction chemotherapy on
disease-free survival (B) or locoregional recurrence-free survival (C).
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ment in HNSCC patients. Higher beta-Tubulin-II and
lower cyclin D1 have been found to strongly associate with
lower response rates to TPF induction chemotherapy
[36,37]. However, before being widely embraced, further
clinical trials on prognostic and/or predictive biomarkers,
alone or in combination, are needed to validate their clin-
ical utility, and to realize the goal of personalized treat-
ment for patients with HNSCC.Conclusions
Out studies suggest that Annexin A1 expression may
serve as a prognostic biomarker in patients with resect-
able locally advanced OSCC. Furthermore, Annexin A1
is a predictive biomarker for response to TPF inductionchemotherapy in patients with moderate/poorly differen-
tiated OSCC.
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